(3S,5R)-Fluvastatin sodium is the (3S,5R)-enantiomer of Fluvastatin. Fluvastatin is a first fully synthetic, competitive HMG-CoA reductase inhibitor (IC50: 8 nM). Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-
17-oxo-4(Z),7(Z),10(Z),13(Z),15(E),19(Z)-Docosahexaenoic acid is a metabolite of lipoxygenase-mediated oxidation of DHA that is produced endogenously by aspirin-enhanced COX-2 activity. It has been shown to activate Nrf2-dependent antioxidant gene expression, to act as a PPARγ agonist (EC50 = ~200 nM), and to inhibit pro-inflammatory cytokine and nitric oxide production at biological concentration ranges (5-25 μM).
Docosapentaenoic acid (DPA) is a ω-3 fatty acid found in fish oils. 17-oxo-7(Z),10(Z),13(Z),15(E),19(Z)-docosapentaenoic acid is a metabolite of lipoxygenase-mediated oxidation of DPA that is produced endogenously by aspirin-enhanced COX-2 activity. It has been shown to activate Nrf2-dependent antioxidant gene expression, to act as a PPARγ agonist (EC50 = ~200 nM), and to inhibit pro-inflammatory cytokine and nitric oxide production at biological concentration ranges (5-25 μM).
(3R,5S)-Fluvastatin, the 3R,5S-isomer of Fluvastatin (XU 62-320 free acid), stands as the inaugural fully synthetic, competitive inhibitor of HMG-CoA reductase, exhibiting an IC50 value of 8 nM. It safeguards vascular smooth muscle cells from oxidative stress by activating the Nrf2-dependent antioxidant pathway.